Table 1.
Clinical characteristics at stable baseline state
| Subjects, n | 30 |
|---|---|
| Male, n (%) | 18 (60) |
| Age (Year) ¥ | 65 (45–81) |
| Smokers, n (%) | 14 (47) |
| Pack year history ¥ | 50 (10–156) |
| On ICS treatment (%) | 20 (90) |
| Co-morbidity – Cardiovascular (%) * | 9 (31) |
| Co-morbidity – Diabetes (%)* | 3 (10) |
| Co-morbidity – Endocrine (%)* | 0 (0) |
| Co-morbidity – Depression (%)* | 6 (21) |
| Co-morbidity – Osteopenia/porosis (%)* | 6 (21) |
| Co-morbidity – Anaemia (%)* | 0 (0) |
| GOLD 2, n (%) | 9 (30) |
| GOLD 3, n (%) | 16 (53) |
| GOLD 4, n (%) | 5 (17) |
| Post-bronchodilator FEV1 (L) | 1.25 (0.52) |
| Post-bronchodilator FEV1% predicted | 47 (18) |
| FEV/FVC ratio, % | 47 (12) |
| Chronic respiratory disease questionnaire, units | 4.11 (0.99) |
| Total visual analogue scale, mm | 156 (77) |
| Proportion taking inhaled corticosteroids, n (%) | 27 (90) |
| Sputum total cell count, ×106/g | 3.50 (2.11 to 5.82) |
| % neutrophil sputum count | 77 (20) |
| Total sputum neutrophil count, ×106/g | 2.80 (1.58 to 4.96) |
| Proportion with positive microbiology culture, n (%) | 9 (30) |
| Colony forming units, ×107 | 1.09 (0.34 to 3.48) |
GOLD - Global Initiative for chronic obstructive lung disease individuals grouped (1–4) by severity of disease; FEV1 – Forced expiratory volume in 1 s; FVC - Forced vital capacity; Chronic Respiratory Disease Questionnaire, scores range between 1 to 7 with higher score representing better health quality; Visual Analogue Scale, performed on 100 mm line from ‘no symptoms’ to ‘worst symptoms’, higher scores represent worse symptoms (total score addition of measured domains: cough, dyspnoea, sputum production and sputum purulence). Unless indicated all tables are mean and standard deviation in brackets. ¶ - Geometric mean and 95% Confidence Intervals. ¥- Mean (range). € Median (IQR). Three patients had no sample available for microbiology culture.* One patient missing co-morbidity data